I undertook my undergraduate medical training at the University of Sheffield, where I completed an intercalated BMedSci degree in pathology in 1995, and qualified in 1998. After completing Basic Surgical Training in South Yorkshire in 2003, I was awarded a Medical Research Council Fellowship (2004-2007) and undertook a PhD researching molecular mechanisms of prostate cancer progression. I then undertook higher surgical training in Urology in both Sheffield and Oxford, whilst in parallel continuing to pursue my prostate cancer research interests, leading to numerous scientific publications in this field under the mentorship of Professor Freddie Hamdy. In 2015, I was appointed Locum Consultant Urologist in Oxford and continued to combine clinical practice, specialising in the diagnosis and management of prostate cancer, with prostate cancer research. In 2017 I was appointed Honorary Consultant Urologist in Oxford.
Associate Professor of Urology
- Cancer Research UK / Royal College of Surgeons of England Clinician Scientist Fellow
- Honorary Urology Consultant
I am a Cancer Research UK Clinician Scientist Fellow (joint with the Royal College of Surgeons of England), which enables me to continue to combine my care of prostate cancer patients with a wide and growing prostate cancer research portfolio, covering the breadth of basic science, translational, and clinical research, at the Nuffield Department of Surgical Sciences.
I have been the Lead Clinician for the VANCE (VAcciNation in prostate CancEr) Clinical trial in Oxford since 2015, and in 2017 I commenced my current position as Honorary Consultant Urologist at the Churchill Hospital in Oxford.
I also deliver undergraduate teaching in surgery and urology to clinical medical students.
- Executive committee member of the Academic Section of the British Association of Urological Surgeons (BAUS) (2017-2019)
- Full member of BAUS, the European Urology Association (EAU), the Association of Academic European Urologists (AAEU), and the American Urology Association (AUA)
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC. et al, (2020), Health Technol Assess, 24, 1 - 176
Prescribing patterns for medical treatment of suspected prostatic obstruction: A spatiotemporal statistical analysis of Scottish open access data
Andreis F. et al, (2020)
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F. et al, (2020), J Immunother Cancer, 8
Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
Sathianathen NJ. et al, (2020), Eur Urol
Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.
Rao SR. et al, (2020), J Mol Diagn, 22, 652 - 669